Dermata Therapeutics, Inc. financial data

Symbol
DRMA, DRMAW on Nasdaq
Location
3525 Del Mar Heights Rd., #322, San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 37 % -1.83%
Return On Equity -192 % +22.4%
Return On Assets -140 % +22%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.03M shares -49.7%
Common Stock, Shares, Outstanding 844K shares -49.7%
Entity Public Float 1.6M USD -66.7%
Common Stock, Value, Issued 84 USD -50%
Weighted Average Number of Shares Outstanding, Basic 1.03M shares +560%
Weighted Average Number of Shares Outstanding, Diluted 1.03M shares +560%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.6M USD -35.7%
General and Administrative Expense 4.05M USD -9.52%
Operating Income (Loss) -9.07M USD +21.3%
Net Income (Loss) Attributable to Parent -8.85M USD +21.5%
Earnings Per Share, Basic 57 USD/shares +91.9%
Earnings Per Share, Diluted 57 USD/shares +91.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.66M USD
Assets 5.07M USD -24.2%
Accounts Payable, Current 453K USD -47.5%
Employee-related Liabilities, Current 594K USD
Liabilities 1.11M USD -42.9%
Retained Earnings (Accumulated Deficit) -71.4M USD -14.2%
Stockholders' Equity Attributable to Parent 3.96M USD -16.5%
Liabilities and Equity 5.07M USD -24.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.93M USD +28.5%
Net Cash Provided by (Used in) Financing Activities 8.49M USD
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 844K shares -49.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.56M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.66M USD -24.1%
Deferred Tax Assets, Valuation Allowance 8.02M USD +46.7%
Deferred Tax Assets, Gross 8.02M USD +46.7%
Deferred Tax Assets, Operating Loss Carryforwards 4.27M USD +43.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 764K USD +18.5%
Additional Paid in Capital 75.3M USD +12%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares